Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia, the RALLY study.
For more information, please visit www.RALLYStudy.com or www.clinicaltrials.gov (NCT04508621).
Upcoming Event
May Investor Summit Virtual Conference
Stock Information
Symbol
Nasdaq: TNXPPrice
Change
MKT Cap
Volume
52 week Low/High
Day Low/High
Company Overview
Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat pain, addiction and psychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix's lead product candidate, TNX-102 SL, is in Phase 3 development as a bedtime treatment for fibromyalgia. Tonix is also developing TNX-102 SL as a bedtime treatment for agitation in Alzheimer's disease. TNX-601 (tianeptine oxalate) is in the pre-IND application stage, also for the treatment of major depressive disorder and PTSD, and is designed for daytime dosing. Tonix's lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.
IR Contact Information
Investor Relations
TONIX Pharmaceuticals
investor.relations@tonixpharma.com
Transfer Agent
vStock Transfer
77 Spruce Street
Suite 201
Cedarhurst, NY 11516
T: 212-828-8436
www.vstocktransfer.com